Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Other Investing Activities

Investing cash flows not reported separately.

Viatris Inc.NASDAQ: VTRS

Other Investing Activities · Q2 FY2026 · quarter ended Jun 2026

Other investing activities turns negative

Q2 FY2026 other investing activities was -$79.2M, compared with $1.6M a year earlier. Trailing-twelve-month other investing activities was -$26.6M.

Context

  • Other investing activities amounted to 0.3% of revenue in FY2025, down 16.5 pp from a year earlier.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near -$79.2M or moves back toward the trailing-twelve-month quarterly average of -$6.65M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$79.2M+3343.5% QoQ
Last fiscal yearDec 2025
-$48.9M-102.0% YoY
LTMJun 2026
-$26.6M-101.5% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5050.0%——
1 year-102.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
(48.9M) USD
Year-over-year change
-102.0%

Other Investing Activities vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -101.5% is the lowest of 10, against a peer median of -9.2%.
  • Other investing activities amounts to 0.2% of revenue for VTRS, versus a peer median of 0.3%.
VTRS Competitors
Other Investing Activities for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹4.64B INR+147.5%—1.4%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$1.22B USD-9.2%+2.3%7.0%
OGNOrganon & Co.LTM Sep 2026$653.78M USD+22236.2%—10.7%
BHCBausch Health Companies Inc.LTM Jun 2026$32.01M USD+1513.4%+63.0%0.3%
VTRSViatris Inc.LTM Jun 2026$26.6M USD-101.5%—0.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$7.41M USD-16.1%+1.1%0.2%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$6.54M USD-95.0%+68.9%0.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$225K USD-98.8%+44.2%0.0%
ALKSAlkermes plcLTM Sep 2026$14K USD+100.0%—0.0%
HLNHaleon plcFY2025£0 GBP-100.0%—0.0%
Peer median (excluding VTRS) —-9.2%+44.2%0.3%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.